Recent research have converged on the convergence of GLP-1|GIP|GCGR stimulant therapies and dopamine signaling. While GLP stimulators are increasingly employed for addressing type 2 diabetes mellitus, their unexpected impacts on motivation circuits, specifically governed by dopamine pathways, are gaining substantial interest. This report provides a